Maze Therapeutics Stock Just Shot Up 56% Pre-Market Today – Here’s What Happened

Maze Therapeutics, Inc. (MAZE) on Thursday announced that it has entered into a securities purchase agreement for the private placement of its securities for gross proceeds of about $150 million. Shares of the company soared 56% in the pre-market session at the time of writing.

The private placement involves the sale of over four million shares of common stock at $16.25  apiece, implying a premium of over 1% from the stock’s closing price on Wednesday. The placement is expected to close on September 12, the company said, while adding that both new and existing investors will participate.

The firm said that the private placement includes participation from Frazier Life Sciences, Deep Track Capital, Driehaus Capital Management, Janus Henderson Investors, Logos Capital, TCGX, and Venrock Healthcare Capital Partners, as well as other healthcare-dedicated funds.

The South San Francisco-based biopharmaceutical company is developing medicines for patients with kidney and metabolic diseases. It stated that it expects to utilize the proceeds from the placement to advance the development of MZE829 in patients with APOL1-mediated kidney disease, initiate mid-stage clinical trials of MZE782 in both phenylketonuria (PKU) and chronic kidney disease (CKD), and continue progress on its research and discovery programs. The company also intends to use the funds for working capital and other general corporate purposes.

Last month, the company said that it ended June with cash and cash equivalents of $264.5 million, which it expects will fund operations into the second half of 2027.

Separately, the company also announced positive clinical results from an early-stage study of MZE782, including “an excellent safety profile, robust target engagement and compelling pharmacodynamic effects.” The firm stated that the study data in 112 healthy volunteers exceeded expectations, enabling mid-stage advancement in the treatment of both PKU and CKD in 2026.

Maze went public in January. The stock is up by 0.4% since its listing. 

Read also: ‘Bitcoin in Consolidation’ – Galaxy’s Mike Novogratz Reportedly Sees Solana, Ethereum Taking Spotlight For Now

For updates and corrections, email newsroom[at]stocktwits[dot]com.